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Metastasis suppressorasis suppressor, N-myc downstream regulated gene-1 (Ndrg-1), has been shown to
reduce the invasion and metastasis of breast, colon, prostate and pancreatic cancer. Among its many
functions, Ndrg-1 is involved in modulating differentiation, proliferation and angiogenesis. However,
knowledge of the molecular targets of Ndrg-1 is limited. The current study has focused on examining the
functions of Ndrg-1 in a number of different cancer cell models including prostate, colon, lung and pancreatic
cancer to elucidate the known pleiotropic nature of this protein. Furthermore, the potential gene targets of
Ndrg-1 were analyzed using whole genome gene array revealing a substantial number of genes whose
expression was affected by this metastasis suppressor. Signiﬁcantly, Ndrg-1 up-regulated thiamine
triphosphatase (Thtpa) expression in three of the four cell models. Thtpa is known to decrease the levels of
the energy currency molecule, thiamine triphosphate, suggesting a potential pathway for the anti-
proliferative effects of Ndrg-1. Furthermore, Ndrg-1 reduced the protein levels of cathepsin C which plays a
role in invasion, indicating a potential mechanism of its anti-metastatic role in pancreatic cancer cells. These
ﬁndings provide a potential link between the observed functions of Ndrg-1 and its molecular targets, further
demonstrating its anti-metastatic effect.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe ability of a tumor to metastasize is a signiﬁcant clinical
problem responsible for poor patient prognosis [1]. Therefore, it is
important to develop treatments that target the metastatic ability of
tumors. A recently identiﬁed group of metastasis suppressor proteins
has provided new insight into the treatment of cancer [2].
One such protein, N-myc downstream regulated gene-1 (Ndrg-1),
has been identiﬁed as a metastasis suppressor [3–6]. Several studies
have demonstrated that Ndrg-1 levels are lower in tumors compared
to adjacent normal tissue [3–6]. Furthermore, forced Ndrg-1 expres-
sion reducedmetastasis [3–6]. In fact, in humanprostate cancer, Ndrg-
1 expressionwas much higher in organ-conﬁned tumors compared to
lymph node or bone metastasis, suggesting that Ndrg-1 was
negatively correlated with metastasis [4]. Studies examining cancer
patient survival rates found that tumors with high Ndrg-1 levels lead
to improved survival compared to matched patients with lower Ndrg-
1 expression [4–6].
Ndrg-1 is a member of the NDRG family which consists of three
other genes, namely Ndrg-2, Ndrg-3 and Ndrg-4 [7,8]. A distinguishing
feature of Ndrg-1 is the three tandem repeats of GTRSRSHTSE in its C-
terminal region, suggesting a unique function [8]. Ndrg-1 has been. Richardson).
l rights reserved.mapped to chromosome 8q24.3, where it encodes a 3.0 kb mRNA that
is translated into a 43 kDa protein [9–11].
Although Ndrg-1 function is unclear, its expression affects
many cellular processes ranging from myelin sheath maintenance to
differentiation [11–17]. In fact, Ndrg-1 appears to function in a
pleiotropic manner dependent on cell type [17,18]. The molecular
targets of Ndrg-1 have yet to be assessed in a range of tumor cells. A
recent study found Ndrg-1 down-regulates activating transcription
factor 3 (ATF3), which plays a role in cell cycle progression and apop-
tosis [19]. However, no complete gene array data have been presented.
Therefore, it was important to examine the potential molecular
targets of Ndrg-1 in a variety of tumor cells to elucidate its cell-speciﬁc
role.
We identiﬁed that Ndrg-1 is up-regulated in cells following iron
(Fe)-depletion using Fe chelators via hypoxia inducible factor-1α
(HIF-1α)-dependent and -independent mechanisms [20]. Further
studies by others using Fe chelators, mimosine and desferrioxamine
(DFO), have extended this [21,22]. Iron chelators are very effective in
reducing tumor growth in a selective manner [23,24] and one agent,
Triapine®, is in clinical trials [25]. The anti-tumor effects of Fe
chelators may be partly due to Ndrg-1 up-regulation, which reduces
cancer cell growth andmetastasis [3–6,26]. Recently, it was found that
Ndrg-1 was activated by hypoxic stress, where it played a protective
role [27,28]. Considering that Fe chelators mimic hypoxia and lead to
Ndrg-1 up-regulation [20], it was important to assess whether this
leads to resistance to these agents. In fact, high Ndrg-1 expressionwas
1982 Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992found to mediate resistance to the topoisomerase inhibitor, CPT-11
[29].
In this investigation, we examined the role of Ndrg-1 in cellular
adhesion, proliferation, and the resistance to anti-proliferative activity
mediated by the Fe chelator, DFO. Furthermore, to investigate the
molecular targets of Ndrg-1, we demonstrate using whole genome
microarray that Ndrg-1 modulates the expression of a variety of genes
including thiamine triphosphatase (Thtpa) and cathepsin C (Ctsc). These
ﬁndings are important in terms of understanding the anti-metastatic
function of Ndrg-1.
2. Materials and methods
2.1. Cell culture
Rat metastatic prostate cancer cells (AT6.1) were a gift from Dr. K.
Watabe (Southern Illinois University School of Medicine, USA) [4].
These cells were stably transfected with the pcDNA3 vector
containing Ndrg-1 cDNA (#7 and #10 clones) or the pcDNA3 vector
alone (# 9 clone) [4]. The human MIAPaCa-2 cells transfected with a
pIRESneo2-Ndrg-1 vector and vector control cells were obtained
from Dr. Michihiko Kuwano (Research Centre for Innovative Cancer
Therapy, Fukuoka, Japan) [6]. Human metastatic lung cancer cells,
H1299, and non-metastatic human colorectal adenocarcinoma cells,
DLD-1, transfected with the tetracycline-inducible human Ndrg-1
vector, pBI-Ndrg-1-EGFP, in a Tet-off system [15] were purchased
from GenHunter (Nashville, TN, USA).
2.2. Western blot and RNA analysis
Western analysis was performed via established protocols [30].
The primary antibodies used were against Ndrg-1 (Zymed, CA, USA),
Thtpa (Abnova Corporation, Taiwan), Ctsc (Abs: L14 and T17; Santa
Cruz, California, USA) and Kifc3 (ProteinTech Group Inc. IL, USA).
Isolation of mRNA was performed using TRIzol® (Invitrogen,
Melbourne, Australia) by standard procedures [31]. RT-PCR was
carried out by established methodology [31] using the primers in
Table 1.Table 1
Primer sequences used to amplify RNA extracted from human and rat cell lines
Primer name Accession no. Oligonucleotides (5′–3′)
Forward Priming site
hβ-actin X00351 CCCGCCGCCAGCTCACCATGG 25–46
rβ-actin NM_031144 GAGGGAAATCGTGCGTGAC 696–715
hNdrg-1 NM_006096 TCACCCAGCACTTTGCCGTCT 394–415
rNdrg-1 AY500369.1 GGATCAGTTGGCTGAAAT 446–464
rHod NM_133621 AGCAGACGCAGAAATGGT 250–268
rKifc3 XM_240978 CTGTGACCTTTGACCCTGAT 1658–1678
rATP6v0e2 NM_001002253 GACAGCCCATTCCTTTGC 75–93
rCtsc NM_017097 GCCCAAACCTGCCCCGATAA 696–716
rScd1 NM_139192 TCCTACACGACCACCACTACC 136–157
rCryl1 NM_175757 TTATGTCCCGCTGGTTGA 516–534
rFmo3 NM_053433 TCGGAGCAAAGCCCAATA 1392–1410
rThtpa NM_001007682 CAGGGCTTGATTGAGGTG 369–387
rCol15a1 XM_216399 CCACCTTCCGAGCGTTTC 3874–3892
rBtg3 NM_019290 TTCCAATGTGGCACCCTT 589–607
hFmo3 NM_006894 TGCCATTCCCACAGTTGA 1207–1225
hHod NM_032495 ATGTCGGCGGAGACCGCGAGC 283–304
hThtpa NM_024328 TTGAGGTGGAGCGAAAGT 753–771
hCol15a NM_001855 CCAAACCCTATTTCAAGTGC 3819–3839
hCtsc NM_001814 CAGACCCCAATCCTAAGCC 933–952
hATP6v0e2 NM_145230 ATAAGAATGCGGCGTGAC 764–782
hKifc3 NM_005550 CGGCTGAAAGGGAACATC 1518–1536
hCryl1 NM_015974 AGTTGTTTGCTGGCTTGG 468–486
hScd1 NM_005063 GCGATATGCTGTGGTGCT 1246–1264
hBtg3 NM_006806 AAATTGCTGCCGTTGTCTT 164–1832.3. Adhesion assays
2.3.1. Cell–Matrix adhesion assay
The ability of cells to adhere to plastic and collagen was analyzed
using standard methods [32,33]. Brieﬂy, 96-well plates were coated
with collagen and allowed to dry. They were then washed in 0.1% BSA
RPMI and blocked with 0.5% BSA RPMI for 1 h, before being washed
again. Wells not coated with collagen were not blocked. Cells were
seeded at 50,000 cells/well and allowed to adhere for 15 min to 1 h at
37°C before being washed twice with PBS. To determine cell number,
the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; Sigma-Aldrich, MO, USA) assay was used [34].
2.3.2. Cell–Cell adhesion assay
Cell–Cell adhesion assays were performed according to established
techniques [35]. Cells were harvested using 1mMEDTA in Ca(II)/Mg(II)
free PBS and washed twice with Hank's balanced salt solution (HBSS)
containing 1% BSA. The cells were then seeded in 24-well plates
(blocked with HBSS containing 2% BSA/3 h/37°C) at a density of 5000
cells/well. As a positive control, 1 mM CaCl2 was added to cells to
promote cell–cell adhesion [35]. The cells were incubated in a gyrating
shaker (37°C/90 rpm/1–2 h) and the reaction terminated by 0.5 mL of
25% formaldehyde/well. Aggregationwas determined as described [35].
2.4. Microarray analysis
AT6.1 cells transfected with human Ndrg-1 (#7 clone) and the
vector control cells (#9 clone) were used for microarray analysis. RNA
was isolated andmicroarray analysis was carried out by the Australian
Genome Research Facility (Victoria, Australia) [36].
A two-phase strategy was used to identify differentially expressed
genes. First, genome-wide screening was performed using Affymetrix
GeneChips® (Millenium Sciences, Victoria, Australia). The empirical
Bayes procedure [37] was applied to detect genes most likely to be
differentially expressed between the #7 and #9 clones. Individual p
values were then adjusted using the Holm step-down procedure to
reduce false positives [38]. Further analysis produced a list of
statistically signiﬁcant (pb0.05) genes with a log2 value N2. DeﬁnitiveProduct size (bp)
s Reverse Priming sites
AAGGTCTCAAACATGATCTGGGTC 421–397 397
CGTACTCCTGCTTGCTGATC 1168–1148 473
GCCACAGTCCGCCATCTT 1010–992 617
ATCTTGAGTAGGGTGGTCTT 958–938 513
ATCTGTCGCTGCTAAACG 897–879 648
TCAGCAAACTTGAGGGAGTAC 2543–2521 886
TTTCACAGCAGGGCATCT 368–349 294
AGTAGTCTAACCCAGTGACTGGATC 1321–1295 626
ACGGCGGGAGTTGTGAGGG 624–605 489
AAGGAGCAGGGGCATTAC 1048–1030 533
TATTGTCGGTGACTCGCAGACATTC 1706–1681 315
CCACGGCATAACCGAAAT 828–810 460
TGCCATGTCCGTGGTTCG 4175–4157 302
AATAAGCCTGATGGTTTTGTC 917–896 329
TCTGAAGTCTCCCGACCA 1595–1577 389
TCTGTGACGGATCTGCAC 500–482 218
AGCCAAAGTCGGCTGTAT 1193–1175 441
CGCCATGCTTCACAGTAGTT 4234–4214 416
AACAATCCAGTAATCCATCCC 1373–1352 441
CCAGAAGAGGTAACAGCAGAC 1254–1233 491
TTGGTGAACTCGGTCGTG 2113–2095 596
CCTTCGCTGTATCTGTCGC 852–833 385
CATAGGCCAGACCGAGGG 1493–1475 248
CACATTGGAAGAGGTGGAAA 707–687 544
1983Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992evidence of differential expression was obtained from RT-PCR of
samples used for microarray analysis and three other RNA samples.
2.4.1. Annotation
Functional annotation of genes was assigned through Gene
Ontology (http://www.geneontology.org) and classiﬁcations obtained
using NetAffx (http://www.affymetrix.com/analysis/index.affx) and
DAVID (http://david.abcc.ncifcrf.gov).
2.4.2. Data availability
The complete microarray data set can be accessed on the Gene
Expression Omnibus (accession number GSE9076; http://www.ncbi.
nlm.nih.gov/geo/).Fig. 1. Ndrg-1 is up-regulated in all cells transfected with human Ndrg-1 and the chelato
incubated with control medium (Con) or this medium containing DFO (250 μM) for 24 h at 37
regulates endogenous rat Ndrg-1 mRNA levels in each clone; (ii) that human Ndrg-1 mRNA
protein expression in the #7, #9 and #10 clones showing higher Ndrg-1 levels in #7 and #10
Ndrg-1 protein in each clone upon incubation with DFO. H1299 and DLD-1 cells transfecte
system) over-express Ndrg-1 mRNA in the absence of tetracycline (C and D, respectively). Nd
Ndrg-1 and DLD-1-Ndrg-1 cells (E and F, respectively). Ndrg-1 protein expression is up-regula
Ndrg-1 cells show increased Ndrg-1 mRNA and protein expression when transfected to ove
Ndrg-1 mRNA and protein levels upon incubation with DFO (I and J, respectively). Results a2.5. Statistics
Data are presented as mean ± standard deviation (number of
experiments) and were compared using the Student's t-test. Results
were considered signiﬁcant when pb0.05.
3. Results
Considering that Ndrg-1 has important roles in metastasis
[4,19,39], understanding its function is important for developing
new treatments. To this end, we investigated Ndrg-1 function in a
variety of cancer cells and its effect on the anti-proliferative activity of
DFO. This was performed using cell lines hyper-expressing Ndrg-1,r, desferrioxamine (DFO), up-regulates endogenous rat Ndrg-1 expression. Cells were
°C. (A) Ndrg-1mRNA expression in the #7, #9 and #10 clones showing: (i) that DFO up-
is only expressed in the #7 and #10 clones but not the vector control clone. (B) Ndrg-1
clones and very low levels in the #9 vector control clone as well as the up-regulation of
d with human Ndrg-1 under the control of a tetracycline-responsive promoter (tet-off
rg-1 protein levels are markedly up-regulated in the absence of tetracycline in H1299-
ted by DFO in H1299 and DLD-1 vector control cells (G and H, respectively). MIAPaCa-2-
r-express Ndrg-1 (I and J, respectively). MIAPaCa-2 vector control cells show increased
re from a typical experiment of 3 performed.
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colon carcinoma and MIAPaCa-2 pancreatic cancer cells. These cell
types were chosen as they have all been shown to be susceptible to the
effects of Ndrg-1 [4,6,15]. Furthermore, Ndrg-1 over-expressing cell
models were used, as the basal levels of this gene are generally low
and its over-expression has been previously shown to have an impact
on each of the cell lines used [4,6,15].
Initial experiments using this range of cell types examined Ndrg-1
levels and the effect of DFO on the expression of this gene. This was
critical to ensure their suitability for the functional studies described
below.
3.1. Ndrg-1 expression in each cell model and its up-regulation upon Fe
chelator treatment
Rat AT6.1 prostate cancer cells transfected with human Ndrg-1
(hNdrg-1) have been shown to be a good model of the metastasis
suppressor role of Ndrg-1 in vivo [4]. We used three clones of AT6.1
cells, two transfected with a pcDNA3 vector containing hNdrg-1
(clones: #7 and #10) and one vector control (clone: #9) [4]. As this
model consists of rat cells transfected with hNdrg-1 cDNA, the
expression of both hNdrg-1 and rat Ndrg-1 (rNdrg-1) mRNA (Fig. 1A)
was assessed. SinceNdrg-1 is up-regulated by Fe chelators [20–22], we
also examined the effect of DFO on Ndrg-1mRNA expression (Fig. 1A).
The AT6.1 clones were incubated with DFO (250 μM) for 24 h at
37°C and RT-PCR was performed to test endogenous rNdrg-1 mRNA
and its response to Fe chelation. This chelator concentration up-
regulated endogenous Ndrg-1 without marked cytotoxicity (N80%
viability), as the incubation was only for 24 h. In each clone, DFO
increased rNdrg-1 mRNA to 2- to 3-fold greater than the control (Fig.
1Ai). Since the AT6.1 clones #7 and #10were transfectedwith hNdrg-1,
they were also assessed by RT-PCR for hNdrg-1mRNA. As anticipated,
hNdrg-1mRNAwas only detected in the #7 and #10 clones (Fig. 1Aii).
An unexpectedﬁndingwas that DFO increased hNdrg-1mRNA levels in
the transfected cells. The reason for this was unclear, as hNdrg-1 is
within a vector regulated by the pcDNA3 promoter.
To determinewhether Ndrg-1 protein expressionwas proportional
to its mRNA levels in AT6.1 cells, Western blots were performed (Fig.
1B). The primary anti-Ndrg-1 antibody used was against hNdrg-1,
although it also detected rNdrg-1 in the #9 vector control (Fig. 1B).
Hence, this antibody detected both hNdrg-1 and rNdrg-1 in a single
band (Fig. 1B). The Western blot results showed signiﬁcantly (pb0.05)
higher Ndrg-1 in #7 and #10 cells, which are transfected with hNdrg-
1, compared to the #9 vector control that has only rNdrg-1 (Fig. 1B).
We also assessed Ndrg-1 expression in human lung cancer (H1299)
and colorectal adenocarcinoma (DLD-1) cells transfected with hNdrg-1
under the control of a tetracycline-responsive promoter (Fig. 1C–F).
These cells over-express Ndrg-1 in the absence of tetracycline (tet-off
system), while Ndrg-1 expression should be suppressed to endogenous
levels when tetracycline is present [15]. To ensure that the tetracycline-
regulatedNdrg-1 systemwas functional, themRNA and protein levels of
hNdrg-1 in theH1299andDLD-1 cellswere analyzedbyRT-PCR (Fig.1C–
D) and Western analysis (Fig. 1E–F) in the presence and absence of
tetracycline. As shown in Fig.1C–D,Ndrg-1was regulatedby tetracycline,
with a marked increase in expression only being found when
tetracycline was absent. Endogenous Ndrg-1 protein in H1299 cells
was virtually undetectable in the vector control samples (Fig. 1E).
However,H1299 cells transfectedwithhNdrg-1 (H1299-Ndrg-1) showed
signiﬁcant (pb0.001) Ndrg-1 protein induction upon tetracycline
removal (Fig.1E). DLD-1 cells endogenously express lowNdrg-1 protein,
as shown in the vector control samples, which were not signiﬁcantly
affected by tetracycline (Fig. 1F). In the absence of tetracycline, DLD-1-
Ndrg-1 cells transfected with the tetracycline-regulated hNdrg-1 vector
also showed signiﬁcantly (pb0.001) increased Ndrg-1 (Fig. 1F).
Further work examined whether endogenous Ndrg-1 was up-
regulated by DFO in H1299 and DLD-1 cells. The H1299 and DLD-1vector control cells were treatedwith 250 μMDFO for 24 h at 37°C and
Ndrg-1 protein examined (Fig. 1G–H). Upon DFO treatment, both cell
types showed a marked increase in Ndrg-1 protein (Fig. 1G–H).
The MIAPaCa-2 pancreatic cell type transfected with Ndrg-1
compared to its vector control was also assessed for Ndrg-1 expres-
sion in the presence and absence of DFO. These studies conﬁrmed that
MIAPaCa-2 cells transfectedwith hNdrg-1 have signiﬁcantly (pb0.001)
higher Ndrg-1 mRNA and protein levels when compared to vector
controls (Fig.1I–J). Furthermore, a 24 h incubation at 37°Cwith 250 μM
DFO markedly increased Ndrg-1 in the vector controls (Fig. 1I–J).
However, the effect of DFO onNdrg-1was not observed in MIAPaCa-2-
Ndrg-1 cells, as these extensively over-express Ndrg-1.
3.2. The role of Ndrg-1 in cell–matrix and cell–cell adhesion
3.2.1. Cell–Matrix adhesion
Cell–Matrix adhesion is a mediator of tumor progression [40]. For
tumor cell migration to occur, cell–matrix adhesion needs to be
reduced [40]. On the other hand, cell–matrix adhesion is a component
of invasion, with some tumors exhibiting increased expression of cell–
matrix adhesion molecules [40]. Furthermore, Ndrg-1 has been
suggested to modulate cell adhesion [3,41] and was important to
assess in the 4 cancer models of Ndrg-1 expression (Fig. 1).
We assessed the roleNdrg-1 plays in cell–matrix adhesion onplastic
and also collagen coated plates over a 15–60 min incubation as an
indication of whether this contributes to its metastasis suppressor
function. Adhesion of AT6.1 cells with high Ndrg-1 levels (#7 and #10)
was compared to the vector control (#9). These results showed that
clones #7 and #10 had signiﬁcantly (pb0.01) lower cell–matrix
adhesion than #9 control cells after incubations of 15 and 30 min on
plastic (Fig. 2A) andat 45 and 60min on collagen (Fig. 2B). This indicates
that AT6.1 cells with high Ndrg-1 take longer to adhere, which may
affect their ability to seed and invade tissues. The MIAPaCa-2, H1299
andDLD-1 cells over-expressingNdrg-1were also assayed for adhesion.
However, Ndrg-1 levels were found to have no effect on cell–matrix
adhesion in these cells (data not shown). These results may be
rationalized considering the pleiotropic roles of Ndrg-1 [17,18,42].
3.2.2. Cell–Cell adhesion
Since Ndrg-1 modulates cell–matrix adhesion in AT6.1 cells (Fig.
2A and B), but not the other cell types, we examined its effect on cell–
cell adhesion in all four models. This was done as cell–matrix adhesion
is a separate process to cell–cell adhesion [43] and Ndrg-1 could affect
each differently. Cells expressing high Ndrg-1 were compared to the
vector controls in an in vitro cell–cell adhesion assay. These results
revealed that AT6.1 cells with high Ndrg-1 expression (clones #7 and
#10; Fig. 1B) formed smaller numbers of aggregates when compared
to control cells (clone #9), which were able to form a large number of
aggregates (Fig. 2C). In fact, while there was 72% aggregation in the
control cells, only 8% and 47% of #7 and #10 cells, respectively, were
able to aggregate (Fig. 2C). While there was a difference in the
aggregation of AT6.1 clones (#7 and #10) with high Ndrg-1
expression, both were signiﬁcantly (pb0.03) lower than the control.
Positive controls treated with CaCl2 resulted in even aggregation
across all three clones, demonstrating their equal ability to form cell–
cell adhesions (data not shown). This suggested in AT6.1 cells that
Ndrg-1 affects cell–cell adhesion in vitro as well as cell–matrix
adhesion. In contrast, H1299, DLD-1 and MIAPaCa-2 cells showed no
signiﬁcant difference in cell–cell adhesion between control cells and
those hyper-expressing Ndrg-1 (data not shown).
3.3. High Ndrg-1 expression induces alterations in morphology and
proliferation in rat prostate cancer cells
Ndrg-1 reduces proliferation of certain cancer cells [15,26] which
may be due to its ability to induce differentiation [3,10,42,44].
Fig. 2. Ndrg-1 expression alters the morphology, cell adhesion and proliferation in some cancer cell types. Cell–Plastic (A) and cell–collagen (B) adhesion assay of AT6.1 cells showing
that the #7 and #10 clones with high Ndrg-1 expression have signiﬁcantly (⁎pb0.01) lower cell tomatrix adhesion at the 15 and 30min time points on plastic and at 45 and 60min on
collagen. (C) Table showing that #7 and #10 clones have signiﬁcantly lower (pb0.03) cell–cell adhesion compared to #9 controls as determined by calculating the percentage of
aggregation. (D) An AT6.1 proliferation assay showing that cells transfected with Ndrg-1 (#7 and #10 clones) have signiﬁcantly (pb0.05) lower proliferation rates than the vector
control #9 clone after 5 days. (Ei) Photomicrograph (200×) of the morphology of AT6.1 cells showing that cells with high Ndrg-1 (#7 and #10) expression have a greater proportion of
spindle-shaped cells than the vector control clone (#9). (Eii) Quantiﬁcation by cell counts demonstrating that the proportion of spindle cells in the clone #9 population with low
Ndrg-1 expression is signiﬁcantly (⁎pb0.002; pb0.005) less than that found for clone #7 and clone #10 that hyper-express Ndrg-1. Results in (A), (B) and (D) are mean ±+ SD from 3
experiments.
1985Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992Moreover, the ability of Ndrg-1 to reduce proliferation and induce
differentiation may contribute to its anti-metastatic effects [3,10].
Considering this, we assessed the effect of Ndrg-1 on proliferationusing prostate, lung, colon and pancreatic cancer cells. The Ndrg-1
over-expressing clones of AT6.1 cells (#7 and #10 clones), as well as
the #9 vector controls, were seeded and their growth examined by
1986 Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992viable cell counts. The #7 and #10 clones, which have the highest
Ndrg-1 (Fig. 1B), had signiﬁcantly lower proliferation (pb0.01) when
compared to the #9 control clone at day 5 (Fig. 2D).
A comparison of the phenotypes displayed by AT6.1 cells revealed
that cells with high Ndrg-1 appeared more differentiated, displaying a
signiﬁcantly (pb0.005) higher number of spindle-shaped cells (see
arrows Fig. 2Ei–Eii). Such morphology has been linked to greater
differentiation in a variety of cell types [45,46]. Moreover, Ndrg-1 has
been associated with differentiation in several cancers [3,4,10].
Previous studies showed that Ndrg-1 hyper-expression leads to
colon cancer cells with spindle-shaped morphology [3], whereas
these cells with low Ndrg-1 were rounded, smaller and clumped [3].
These ﬁndings agree with this study, where prostate cancer cells with
low Ndrg-1 were small, spherical and had a tendency to aggregate
(Fig. 2Ei). This suggested that Ndrg-1 reduces AT6.1 cell proliferation
via induction of differentiation.
The proliferation of lung cancer (H1299), colon adenocarcinoma
(DLD-1) and MIAPaCa-2 pancreatic carcinoma cells was also analyzed.
In all cases, cells with high Ndrg-1 showed no signiﬁcant difference in
growth or morphology compared to controls (data not shown).
3.4. Ndrg-1 does not modulate cellular sensitivity to DFO
Ndrg-1 is involved in generating resistance to CPT-11 [14,29].
Interestingly, Ndrg-1 was identiﬁed as a stress response gene which
protects cells from insults, e.g., hypoxia [20,27,28] which may be
responsible for the resistance observed to CPT-11. It was shown
previously [20–22] and in this investigation (Fig. 1) that Fe chelators
up-regulate Ndrg-1. Considering the development of chelators for
cancer treatment [23–25,47], it was important to assess if Ndrg-1
modulated sensitivity to DFO.
We analyzed proliferation of AT6.1, H1299, DLD-1 and MIAPaCa-2
cells with high or low Ndrg-1 at different DFO concentrations (3.125,Fig. 3. Ndrg-1 over-expression in (A) AT6.1, (B) H1299, (C) DLD-1 and (D) MIAPaCa-2 cells doe
of DFO (3.125–25 μM) for 6 days at 37°C and then cellular density measured by the MTT as6.25, 12.5 or 25 μM) over 6 days (Fig. 3A–D). For all cell types, DFO
decreased proliferation as a function of concentration (Fig. 3A–D).
However, cells over-expressing Ndrg-1 showed no signiﬁcant differ-
ence in susceptibility to the anti-proliferative effects of DFO compared
to their controls indicating that the difference in expression did not
alter the response.
3.5. Gene array reveals that Ndrg-1 affects expression of a range of gene
groups
As suggested by the functional analyses of Ndrg-1 above and by
others, the role of Ndrg-1 is pleiotropic [3–6,13–15,26], suggesting it is
involved in multiple pathways and has numerous targets depending
on the cell type. To elucidate the molecular targets of Ndrg-1, we
performed an Affymetrix whole genome microarray examining
differential gene expression in AT6.1 cells expressing high Ndrg-1
(#7) compared to vector control cells (#9). This cell type was chosen
considering the clear effects of Ndrg-1 hyper-expression on prolifera-
tion, cell–matrix and cell–cell adhesion (Fig. 2A–E). Also, studies using
AT6.1 cells hyper-expressing Ndrg-1 demonstrate that this molecule
inhibits metastasis in vivo [4]. Hence, these cells represent a good
model to identify molecular targets of Ndrg-1.
The statistically signiﬁcant (pb0.05) differentiallyexpressed genes in
AT6.1 cells were grouped into 9 functional categories (Fig. 4A–B). These
included genes involved in ribosome and protein synthesis, cellmotility,
stress response, proliferation, cell metabolism, lipid metabolism, the
immune response, apoptosis and cell communication (Fig. 4A–B).
The Affymetrix® microarray revealed the differential expression
of numerous genes between AT6.1 cells hyper-expressing Ndrg-1
and control cells. The top statistically signiﬁcant (pb0.05) up- and
down-regulated genes with a log2 value greater than 2 are shown in
Table 2. To validate the microarray, mRNA expression was examined
using RT-PCR. Due to the large number of signiﬁcantly altereds not alter their sensitivity to DFO. Cells were incubated with increasing concentrations
say. Results are mean ± SD (3 experiments).
Fig. 4. Microarray analysis of AT6.1 cells reveals multiple gene targets. AT6.1 cells with high Ndrg-1 expression (#7) and the vector control cells (#9) with low Ndrg-1 levels were
analyzed by whole genome microarray (Affymetrix Rat Expression Array 230 2.0 chip®) for differential gene expression. The statistically signiﬁcant (pb0.05) genes were analyzed
further to determine the functional groups of genes found to be: (A) down-regulated or (B) up-regulated in AT6.1 cells with high Ndrg-1 (#7) relative to low Ndrg-1 expression (#9).
Functional analysis was examined using the comprehensive functional annotation software (DAVID, http://david.abcc.ncifcrf.gov). (C) RT-PCR data validating the expression of
statistically signiﬁcant alterations in gene expression in AT6.1 cells with high Ndrg-1 (#7 and #10) relative to lowNdrg-1 expression (#9). (D) Densitometric assessment of the RT-PCR
data shown in (C). Results in (C) and (D) are from a typical experiment of 3–5 performed.
1987Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992genes, it was not possible to analyze each using this method. Therefore,
ten of themost statistically signiﬁcant geneswere chosen based on fold
change and function. To ensure the alterations in gene expressionwerenot simplydue to clonal variation, two clones ofNdrg-1over-expressing
AT6.1 cells (clones #7 and #10) were used in the validation and
compared to the control (#9) clone. Furthermore, each genewas tested
Table 2
List of statistically signiﬁcant (pb0.05) differentially expressed genes in AT6.1 cells with a log2 value greater than 2
Affymetrix ID Gene title Gene symbol log2 ratio p Value
1374778_at Cathepsin C Ctsc 7.03 0.000
1369503_at Amylase 2, pancreatic Amy2 5.76 0.023
1391456_at Junctional adhesion molecule 3 Jam3 4.52 0.000
1377457_a_at Sortilin-related receptor, LDLR class A repeats-containing Sorl1 4.47 0.006
1367899_at Coagulation factor II (thrombin) receptor F2r 4.28 0.000
1368829_at Fibrillin 1 Fbn1 4.20 0.025
1388713_at Thiamine triphosphatase Thtpa 3.93 0.000
1368304_at Flavin containing monooxygenase 3 Fmo3 3.86 0.000
1372639_at Tripartite motif-containing 54 Trim54 3.77 0.036
1389374_at Kinesin family member C3 Kifc3 3.57 0.002
1370831_at Monoglyceride lipase Mgll 3.37 0.000
1375951_at Thrombomodulin Thbd 3.18 0.000
1369679_a_at Nuclear factor I/A Nﬁa 3.16 0.004
1368655_at Proteoglycan peptide core protein Pgsg 3.03 0.000
1388395_at G0/G1 switch gene 2 G0s2 2.82 0.000
1368247_at Heat shock 70 kDa protein 1A Hspa1a 2.80 0.000
1375043_at FBJ murine osteosarcoma viral oncogene homolog Fos 2.80 0.000
1370987_at Sialophorin Spn 2.77 0.000
1372439_at Procollagen, type IV, alpha 1 Col4a1 2.76 0.000
1384180_at Interferon-induced protein with tetratricopeptide repeats 2 Iﬁt2 2.72 0.000
1383575_at Catenin (cadherin-associated protein), delta 2 Ctnnd2 2.68 0.003
1388798_at Ubiquitin-conjugating enzyme E2E 2 Ube2e2 2.46 0.036
1372835_at Ras homolog gene family, member J Rhoj 2.44 0.001
1371824_at Adenylate kinase 3-like 1 Ak3l1 2.42 0.003
1373245_at Procollagen, type IV, alpha 1 Col4a1 2.41 0.000
1367554_at Secretoglobin, family 2A, member 1 Scgb2a1 2.33 0.000
1390195_at Pleckstrin and Sec7 domain containing 4 Psd4 2.32 0.014
1387988_at Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Hsd3b1 2.29 0.001
1373351_at Ankyrin 2, neuronal Ank2 2.29 0.000
1383119_at Opioid growth factor receptor-like 1 Ogfrl1 2.25 0.000
1387018_at Arg/Abl-interacting protein ArgBP2 Argbp2 2.19 0.000
1373577_at Neuropilin 1 Nrp1 2.05 0.000
1377497_at 2¢–5′ oligoadenylate synthetase-like 1 Oasl1 2.03 0.008
1389067_at Solute carrier organic anion transporter family, member 4a1 Slco4a1 2.01 0.007
1368322_at Superoxide dismutase 3, extracellular Sod3 −2.01 0.000
1367923_at Acyl-CoA synthetase bubblegum family member 1 Acsbg1 −2.05 0.004
1367816_at Homeobox only domain Hod −2.10 0.000
1372649_at Heat shock 27 kDa protein family, member 7 (cardiovascular) Hspb7 −2.15 0.000
1377599_at Lipin 1 Lpin1 −2.22 0.008
1370158_at Myosin, heavy polypeptide 10, non-muscle Myh10 −2.29 0.000
1367949_at Proenkephalin 1 Penk1 −2.32 0.000
1367905_at Ectonucleotide pyrophosphatase/phosphodiesterase 3 Enpp3 −2.37 0.002
1391052_at DOM-3 homolog Z Dom3z −2.73 0.000
1391442_at EH-domain containing 3 Ehd3 −2.74 0.000
1368072_at B-cell translocation gene 3 Btg3 −2.80 0.000
1388939_at Procollagen, type XV Col15a1 −2.94 0.015
1386899_at Cathepsin H Ctsh −3.20 0.000
1394022_at Inhibitor of DNA binding 4 Id4 −3.51 0.038
1368080_at Response gene to complement 32 Rgc32 −3.54 0.000
1376051_at Crystallin, lamda 1 Cryl1 −3.65 0.000
1370355_at Stearoyl-Coenzyme A desaturase 1 Scd1 −3.92 0.000
1368633_at Cysteine-rich secretory protein 1 Crisp1 −4.15 0.000
1398245_at Synuclein, gamma Sncg −4.34 0.000
1389362_at Protein tyrosine phosphatase, non-receptor type 3 Ptpn3 −4.43 0.000
1387029_at Complement component factor H Cfh −5.13 0.000
1372907_at ATPase, H+ transporting, V0 subunit E isoform 2 Atp6v0e2 −5.65 0.005
Data obtained from using Affymetrix GeneChips®.
1988 Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992by RT-PCR at least 3 times in different lysates to conﬁrm the result. Nine
of the ten genes assessed were validated by RT-PCR. Indeed, the down-
regulation of Hod, Col15a1, Btg3, Cryl1 and Scd1 and the up-regulation
of Fmo3, Thtpa, Ctsc and Kifc3 were conﬁrmed in each of the Ndrg-1
over-expressing clones (Fig. 4C–D).
Further studies then examined the expression of these conﬁrmed
genes in control and Ndrg-1 hyper-expressing H1299, DLD-1 and
MIAPaCa-2 cells. Considering the reported pleiotropic effects of
Ndrg-1, these studies were performed to investigate if Ndrg-1
targets the same genes in other cell types. However, most of the
genes affected by Ndrg-1 in AT6.1 cells were not differentially
expressed in H1299, DLD-1 and MIAPaCa-2 cells (data not shown).
Together, these observations conﬁrm the difference in the pheno-type of AT6.1 cells compared to H1299, DLD-1 and MIAPaCa-2 cells
observed when assessing cell–matrix and cell–cell adhesion as well
as proliferation.
3.6. Ndrg-1 hyper-expression up-regulates Thtpa in H1299, DLD-1 and
MIAPaCa-2 cells and down-regulates cathepsin C in MIAPaCa-2 cells
Considering that eight genes were conﬁrmed to be differentially
expressed at the mRNA level in two hyper-expression clones of AT6.1
cells (Fig. 4C–D), we examined their protein expression. Antibodies
were available or found suitable for Western analysis for three of the
eight differentially expressedmolecules, namely Thtpa, Ctsc and Kifc3.
Hence, the expression of these molecules was then examined.
Fig. 5. Assessment of Ndrg-1 target genes identiﬁed fromwhole genome gene array demonstrates that Thtpa and Ctsc aremodulated by Ndrg-1. (A) Thtpa protein expression in AT6.1
clones #7, #9 and #10 showing no signiﬁcant difference regardless of Ndrg-1 levels. (B) Thtpa and Ctsc mRNA expression in H1299 and H1299-Ndrg-1 cells is not modulated by
alterations in Ndrg-1 expression. (C) Thtpa and CtscmRNA expression in DLD-1 and DLD-1-Ndrg-1 cells is not modulated by alterations in Ndrg-1 expression. (D) ThtpamRNA levels
are not altered in MIAPaCa-2 cells with high or lowNdrg-1 expression, while CtscmRNA expression is down-regulated in cells with high Ndrg-1 expression. (E) Thtpa protein levels in
H1299 cells are increased in cells with high Ndrg-1 expression. (F) Thtpa protein expression is up-regulated in DLD-1 cells with high Ndrg-1 expression. (G) Thtpa protein expression
is up-regulated in MIAPaCa-2 cells with high Ndrg-1 expression, while Ctsc protein expression is down-regulated in cells with high Ndrg-1 levels. Results are representative of 3
separate experiments.
1989Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992Since ThtpamRNAwas up-regulated in AT6.1 cellswith highNdrg-1
(Fig. 4C–D), we examined the effect of Ndrg-1 over-expression on
Thtpa protein levels. However, we found no signiﬁcant difference in
Thtpa protein over 3 experiments regardless of Ndrg-1 levels in AT6.1
cells (Fig. 5A). We then assessed whether Ndrg-1 affected Thtpa
expression in all other cell types at both the mRNA and protein levels.
Interestingly, ThtpamRNAwas not signiﬁcantly modulated by Ndrg-1
in any of these cells (Fig. 5B–D). However, examining Thtpa protein
expression (Fig. 5E–G), this was found to be signiﬁcantly (pb0.05) up-
regulated in the DLD-1-Ndrg-1 cells (Fig. 5F) and MIAPaCa-2 (Fig. 5G)
cell types over 3 experiments.
The gene identiﬁed to be most up-regulated at the mRNA level by
Ndrg-1 in AT6.1 cells by microarray and RT-PCR was Ctsc (Table 2; Fig.
4C–D). Surprisingly, further studies examining Ctsc protein expressionin AT6.1 cells showed that it was not affected byNdrg-1 expression (data
not shown). In fact,Western analysis using two different Ctsc antibodies
gave the same negative result. Furthermore, Ctsc expression in H1299
andDLD-1 cellswas also unaffected at themRNA (Fig. 5B–C) and protein
levels (data not shown). However, examining MIAPaCa-2 pancreatic
cancer cells, Ctsc mRNA (Fig. 5D) and protein levels (Fig. 5G) were
signiﬁcantly (pb0.001) down-regulated by high Ndrg-1 expression.
Interestingly, Kifc3, which is involved in microtubule dynamics
[48] and shown to be signiﬁcantly up-regulated by Ndrg-1 in AT6.1
cells at the mRNA level (Fig. 4C–D), was unaffected at the protein level
in this cell type (data not shown). Furthermore, Kifc3 was not
differentially expressed in H1299, DLD-1 or MIAPaCa-2 cells at the
mRNA or protein levels (data not shown), indicating that Ndrg-1 does
not modulate the expression of this protein in these cell lines.
1990 Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992In summary, the gene expression studies above demonstrate that
Ndrg-1 up-regulated Thtpa expression in three of the four models at
the protein level. Furthermore, Ctsc protein levels were reduced by
Ndrg-1 in MIAPaCa-2 cells.
4. Discussion
Tumor metastasis leads to signiﬁcant clinical problems, contribut-
ing to poor prognosis [1]. Recently, strategies to prevent cancer
metastasis have focused on a new group of proteins, the metastasis
suppressors [2,49]. The recently discovered metastasis suppressor,
Ndrg-1, has been demonstrated to function by affecting differentia-
tion, proliferation and invasion [3–6,14,15,39]. Although numerous
potential functions for Ndrg-1 have been described, its precise
molecular function remains unclear. The current study has further
examined Ndrg-1 function in a number of different cancer models and
assessed its role in the inhibition of proliferation mediated by Fe
chelators, a potential new form of chemotherapy [23–25]. Further-
more, to our knowledge, this is the ﬁrst time that a full gene array
analysis has been reported which identiﬁes molecular targets of Ndrg-
1 which may be responsible for its anti-metastatic effects.
An important component of tumor metastasis is the adhesive
properties of cancer cells, and hence, this property could be a target of
the metastasis suppressor function of Ndrg-1. To examine whether
Ndrg-1 reduces metastasis via cell adhesion, we performed cell–
matrix and cell–cell adhesion assays on all four cell models. We found
that Ndrg-1 reduced cell–matrix (Fig. 2A and B) and cell–cell adhesion
(Fig. 2C) in AT6.1 cells, there being no effect in other cell types
examined. Considering this, reduced cell adhesion can be either pro-
or anti-metastatic [40]. In a primary tumor mass, cells with reduced
cell adhesion may have a greater metastatic potential, as they are
more likely to detach and metastasize [40]. On the other hand,
decreased cell adhesionmay impair the ability of tumor cells to adhere
and invade potential sites of metastasis [40]. The ability of Ndrg-1 to
reduce cell adhesion in AT6.1 cells may suggest an anti-metastatic
role, since high Ndrg-1 expression in this cell type reduces lung
metastasis in vivo [4]. In addition, it has also been reported in prostate
cancer cells, that reduced cell adhesion contributed to decreased cell
migration and metastasis [50]. Others have reported a link between
Ndrg-1 and a key adhesion molecule, E-cadherin, suggesting that
Ndrg-1 up-regulates E-cadherin expression and its re-cycling [3,41].
However, we observed no alteration in E-cadherin in AT6.1 cells with
high or low Ndrg-1 expression (data not shown), and thus, this could
not explain the alterations in adhesion in this cell type.
Numerous investigations have found that Ndrg-1 modulates
differentiation leading to reduced proliferation [3,44]. Following our
observation that Ndrg-1 over-expression changes the morphological
phenotype of AT6.1 cells in a manner consistent with increased
differentiation (Fig. 2Ei, ii), it was imperative to examine whether this
reduces proliferation. Over-expression of Ndrg-1 signiﬁcantly reduced
AT6.1 proliferation (Fig. 2D), while having no effect on growth of other
cell types. This suggests that in AT6.1 cells, the effect of Ndrg-1 on
reducing proliferation may be due to its ability to induce differentia-
tion. Further evidence supporting the role of Ndrg-1 in AT6.1
differentiation comes from our gene array analysis. Among the top
200 statistically signiﬁcant differentially expressed genes, 5 play
signiﬁcant roles in cell differentiation. One of these is Hod, a gene
found to be reduced by Ndrg-1 expression (Fig. 4C–D) which belongs
to a family of homeobox genes shown to be up-regulated in prostate
cancer leading to reduced differentiation [51]. The others include
S100a10, Ctgf, Enpp3 and Spp1, all of which are down-regulated by
Ndrg-1 and have been shown to negatively regulate cell differentia-
tion [52–55].
Our results clearly indicate that Ndrg-1 has different effects
depending on the cell type in which it is expressed. Numerous studies
have also demonstrated the pleiotropic nature of Ndrg-1 in terms of itsfunctionbetweendifferent cell types. Clearly, theAT6.1 cell represents a
prostate cancer model, while the other lines represent lung, colon and
pancreatic tumor lines. Our gene array analysis demonstrated thatmost
of the Ndrg-1 target genes in AT6.1 were not affected in the other cell
lines. Furthermore, Ctsc expression was up-regulated in AT6.1 cells,
while it was down-regulated in theMIAPaCa-2 line (Figs. 4 C–D and 5D,
G). Thus, the alterations in target gene expression in AT6.1 relative to
the other cell typeswill probably lead to different functional behaviour.
Up-regulation of Ndrg-1maycontribute to reducingmetastasis and
improving patient prognosis [4,5,14]. One promising new class of anti-
cancer agents, namely Fe chelators [23–25], were found to up-regulate
Ndrg-1 in many different cancer cell types [20–22] (Fig. 1). Following
reports that highNdrg-1 expression leads to increased resistance to the
anti-cancer drug CPT-11 [14,29], it was important to assess whether
Ndrg-1would affect cancer cell sensitivity to Fe chelators. For each cell
type tested, the proliferation rate declined with increasing DFO
concentration (Fig. 3A–D). However, there was no signiﬁcant differ-
ence in DFO mediated inhibition of proliferation between cells with
high and low Ndrg-1 expression, suggesting that Ndrg-1 does not
mediate increased resistance to Fe chelators. It was surprising that
upon incubation with DFO, cells with higher Ndrg-1 did not show
decreased proliferation relative to controls. This indicates that other
mechanisms are also important for inhibiting proliferation upon Fe-
depletion, including inhibition of ribonucleotide reductase [56],
decreased cyclin D1 expression [57] and down-regulation of p21
protein [31] that can induce apoptosis (for review see [58]).
The results of our functional studies of Ndrg-1 prompted explora-
tion of its molecular targets in different cells to explain its cell-speciﬁc
effects observed here and by others [17,18,42]. Hence, we carried out a
whole genome microarray analysis of AT6.1 cells transfected with
Ndrg-1 (#7) compared to its vector control (#9) to examine its
potential molecular targets. This cell type was chosen because
increased Ndrg-1 expression altered its phenotype leading to
decreased adhesion and proliferation. Moreover, previous studies
demonstrated that AT6.1 clone#7 led to reducedmetastasis to the lung
relative to clone #9 [4]. Thus, the AT6.1 cell line was an appropriate
model to examine Ndrg-1 molecular targets. Our gene array demon-
strated that Ndrg-1 modulates the expression of a range of genes
reﬂecting the numerous functions associated with this protein [17].
These results revealed that 28% of all genes down-regulated by Ndrg-1
were involved in protein synthesis, with most being members of the
Rpl and Rps families, which are structural components of ribosomes
[59]. Moreover, a proteomic study examining molecular targets of
Ndrg-1 in human prostate cancer cells also revealed a large number of
ribosomal proteinsmodulated byNdrg-1 [60]. This suggests that Ndrg-
1 may affect translation, which could contribute to the reduced
proliferation observed in AT6.1 cells (Fig. 2D).
The genes most signiﬁcantly up-regulated by Ndrg-1 included
Fmo3, Ctsc, Thtpa and Kifc3 which are involved in xenobiotic
metabolism [61], proteolysis [62], energy metabolism [63] and
microtubule movement [48], respectively. On the other hand, the
most signiﬁcantly down-regulated genes by Ndrg-1 included Hod,
Col15a1, Btg3, Cryl1 and Scd1, that are involved in the regulation of
transcription [64], cell adhesion [65], proliferation and cell cycle
progression [66], fatty acid metabolism [67] and lipid metabolism
[68], respectively. Surprisingly, when these genes were examined in
Ndrg-1 over-expressing H1299, DLD-1 and MIAPaCa-2 cells, there was
no difference in expression between cells over-expressing Ndrg-1 and
their relevant controls. This is another example of the cell-speciﬁc
effects of Ndrg-1, showing for the ﬁrst time that this protein targets
different molecules depending on the cell type it is expressed in.
Moreover, the differential expression of these genes in the AT6.1 cells
was found to be consistent in two different Ndrg-1 over-expressing
clones (#7 and #10) when compared to the control clone (#9). This
not only further validates the microarray result, but it also suggests
that the result was not due to clonal variation.
1991Z. Kovacevic et al. / Biochimica et Biophysica Acta 1783 (2008) 1981–1992A further analysis of the Ndrg-1 targets at the protein level
revealed that Thtpa was up-regulated signiﬁcantly in DLD-1 and
MIAPaCa-2 cells where Ndrg-1 was over-expressed (Fig. 5E–G).
Previous studies have shown that Thtpa is involved in hydrolyzing
thiamine triphosphate, which is an important energy currency
molecule [69]. Therefore, Thtpa up-regulation by Ndrg-1 may
decrease the available energy as thiamine triphosphate, leading to
reduced growth and metastasis suppression. Indeed, for MIAPaCa-2
cells, others have observed a reduction in growth and angiogenesis in
vivo following the up-regulation of Ndrg-1 [6]. However, as demon-
strated by the AT6.1 microarray analysis, Ndrg-1 has numerous
molecular targets any of which, alone or in combination with other
molecules, may contribute to its anti-metastatic effect.
The most markedly up-regulated gene in AT6.1 cells by Ndrg-1 was
Ctsc, which was increased 380-fold compared to control cells (Fig. 4C–
D), while there was no change in its protein expression. A possible
reason for this observation may be that CtscmRNAwas not translated
or the protein was rapidly degraded. A similar phenomenon under
other experimental conditions has been observed for p21, which was
up-regulated at the mRNA level, but down-regulated at the protein
level [31]. Hence, Ndrg-1 may also induce post-transcriptional
alterations resulting in reduced protein synthesis of Ctsc. As previously
described, our current results and those of others [60] have revealed
that Ndrg-1 down-regulates structural components of the ribosome,
which may contribute to this effect.
Interestingly, in contrast to the observation in AT6.1 cells, Ctsc was
found to be down-regulated in response to Ndrg-1 over-expression in
MIAPaCa-2 cells (Fig. 5D, G). Considering this, Ctsc is a cysteine
proteinase that plays a role in pancreatic cancer progression [62,70]
and Ndrg-1 has been shown to reduce angiogenesis and tumor growth
in pancreatic cancer [6]. Thus, the link between Ndrg-1 and Ctsc could
potentially explain the anti-metastatic function of the former in
pancreatic cancer.
Overall, this study identiﬁed numerous genes which were altered
when Ndrg-1 was over-expressed. While Ndrg-1 is not a transcription
factor itself, it could potentially change gene expression by other
mechanisms, such as protein interactions with other transcription
factors. Indeed, examination of the top 200 signiﬁcantly altered genes
derived from our gene array analysis revealed Ndrg-1 altered
expression of at least 6 different transcription factors (see Gene
Expression Omnibus; accession number GSE9076; http://www.ncbi.
nlm.nih.gov/geo/). One of these was Hod, which has been conﬁrmed
by RT-PCR to be down-regulated in two Ndrg-1 over-expressing AT6.1
clones (Fig. 4C, D). Hence, these transcription factors may be
responsible for the altered gene expression mediated by Ndrg-1. As
demonstrated in this study (Fig. 4A) and by others [60], another
mechanism by which Ndrg-1 inﬂuences gene expression may involve
its effect on reducing expression of many genes involved in ribosome
and protein synthesis.
In conclusion, this study examined the effect of Ndrg-1 over-
expression in four cancer cell models and our results suggest that it
has speciﬁc functions which may depend on the cell type. The
pleiotropic nature of Ndrg-1 has been suggested previously, but has
not been extensively examined until now. The potential gene targets
of Ndrg-1 in rat prostate cancer cells were examined, revealing
multiple molecules that may be responsible for the functions of this
protein, including Thtpa and Ctsc.
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